The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature

Cancer Research

Volumn 70, Issue 11, 2010, Pages 4509-4519

  Li, Luowei ^a   Shukla, Suneet ^a   Lee, Andrew ^a   Garfield, Susan H ^b   Maloney, David J ^a   Ambudkar, Suresh V ^a   Yuspa, Stuart H ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; DEXAMETHASONE; EUPHORBIA EXTRACT; GLYCOPROTEIN P; INGENOL 3 ANGELATE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MULTIDRUG RESISTANCE PROTEIN 1; PEP 005; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE C; TARIQUIDAR; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD VESSEL INJURY; CANCER CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG TRANSPORT; ENDOTHELIUM CELL; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VIVO STUDY; KERATINOCYTE; MELANOMA; MOUSE; NONHUMAN; PHOTOAFFINITY LABELING; PRIORITY JOURNAL; PROTEIN FUNCTION; SKIN BLEEDING; SKIN FIBROBLAST; SKIN INFLAMMATION; SKIN PENETRATION; SQUAMOUS CELL CARCINOMA; SUBCUTANEOUS HEMORRHAGE; TUMOR VASCULARIZATION;

ADMINISTRATION, TOPICAL; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DITERPENES; DRUG ERUPTIONS; ENZYME ACTIVATION; HUMANS; KERATINOCYTES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; P-GLYCOPROTEIN; PROTEIN BINDING; PROTEIN KINASE C; SKIN; SKIN NEOPLASMS; TETRADECANOYLPHORBOL ACETATE;

EID: 77953155672     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-4303     Document Type: Article

References (45)

1. Lee DA, Miller SJ. Nonmelanoma skin cancer. Facial Plast Surg Clin North Am 2009;17:309-324
2. Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer 2008;8:743-754
3. Dlugosz AA, Talpaz M. Following the hedgehog to new cancer therapies. N Engl J Med 2009;12:1164-1178
4. Dlugosz A, Merlino G, Yuspa SH. Progress in cutaneous cancer research. J Invest Dermatol Symp Proc 2002;7:17-26.
5. Li L, Lorenzo PS, Bogi K, Blumberg PM, Yuspa SH. Protein kinase Cδ targets mitochondria, alters mitochondrial membrane potential, and induces apoptosis in normal and neoplastic keratinocytes when overexpressed by an adenoviral vector. Mol Cell Biol 1999;19:8547-8558 (Pubitemid 30414048)
6. Strickland JE, Dlugosz AA, Hennings H, Yuspa SH. Inhibition of tumor formation from grafted murine papilloma cells by treatment of grafts with staurosporine, an inducer of squamous differentiation. Carcinogenesis 1993;14:205-209 (Pubitemid 23143395)
7. Denning MF, Wang Y, Nickoloff BJ, Wrone-Smith T. Protein kinase Cδ is activated by caspase-dependent proteolysis during ultraviolet radiation-induced apoptosis of human keratinocytes. J Biol Chem 1998;273:29995-30002.
8. Denning MF, Dlugosz AA, Howett MK, Yuspa SH. Expression of an oncogenic rasHa gene in murine keratinocytes induces tyrosine phosphorylation and reduced activity of protein kinase Cδ. J Biol Chem 1993;268:26079-26081 (Pubitemid 2013459)
9. D'Costa AM, Robinson JK, Maududi T, Chaturvedi V, Nickoloff BJ, Denning MF. The proapoptotic tumor suppressor protein kinase C-δ is lost in human squamous cell carcinomas. Oncogene 2006;25:378-386
10. Hampson P, Chahal H, Khanim F, et al. PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the δ isoform of PKC. Blood 2005;106:1362-1368
11. Thomson C, Wilkie J. The conformations and electrostatic potential maps of phorbol esters, teleocidins and ingenols. Carcinogenesis 1989;10:531-540 (Pubitemid 19089920)
12. Kedei N, Lundberg DJ, Toth A, Welburn P, Garfield SH, Blumberg PM. Characterization of the interaction of ingenol 3-angelate with protein kinase C. Cancer Res 2004;64:3243-3255 (Pubitemid 38581429)
13. Adolf W, Chanai S, Hecker E. 3-O-angeloylingenol, the toxic and skin irritant factor from latex of Euphorbia antiquorium L. (Euphorbiaceae) and from a derived Thai purgative and anthelimintic (vermifuge) drug. J Sci Soc (Thailand) 1983;9:81-88
14. Ogbourne SM, Suhrbier A, Jones B, et al. Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death. Cancer Res 2004;64:2833-2839
15. Siller G, Gebauer K, Welburn P, Katsamas J, Ogbourne SM. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study. Australas J Dermatol 2009;50:16-22.
16. Challacombe JM, Suhrbier A, Parsons PG, et al. Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. J Immunol 2006;177:8123-8132
17. Yuspa SH, Hawley-Nelson P, Koehler B, Stanley JR. A survey of transformation markers in differentiating epidermal cell lines in culture. Cancer Res 1980;40:4694-4703 (Pubitemid 11199740)
18. 2+ inhibits murine keratinocyte differentiation in vitro. J Cell Physiol 1995;163:105-14.
19. Sauna ZE, Peng XH, Nandigama K, Tekle S, Ambudkar SV. The molecular basis of the action of disulfiram as a modulator of the multidrug resistance-linked ATP binding cassette transporters MDR1 (ABCB1) and MRP1 (ABCC1). Mol Pharmacol 2004;65:675-84.
20. Shen DW, Fojo A, Chin JE, et al. Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification. Science 1986;232:643-5.
21. Katayama K, Yoshioka S, Tsukahara S, Mitsuhashi J, Sugimoto Y. Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein. Mol Cancer Ther 2007;7:2092-102.
22. Cataisson C, Pearson AJ, Torgerson S, Nedospasov SA, Yuspa SH. Protein kinase Cα-mediated chemotaxis of neutrophils requires NF-κB activity but is independent of TNFα signaling in mouse skin in vivo. J Immunol 2005;174:1686-92.
23. de Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005;7:411-23.
24. Shukla S, Robey RW, Bates SE, Ambudkar SV. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos 2009;37:359-65.
25. Slaga TJ, Scribner JD. Inhibition of tumor initiation and promotion by anti-inflammatory agents. J Natl Cancer Inst 1973;51:1723-25.
26. Fischer SM, Furstenberger G, Marks F, Slaga TJ. Events associated with mouse skin tumor promotion with respect to arachidonic acid metabolism: a comparison between SENCAR and NMRI mice. Cancer Res 1987;47:3174-9.
27. Lum H, Malik AB. Regulation of vascular endothelial barrier function. Am J Physiol 1994;267:L223-41.
28. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: from genomics to mechanism. Oncogene 2003;22:7468-85.
29. Ito K, Nguyen HT, Kato Y, et al. P-glycoprotein (Abcb1) is involved in absorptive drug transport in skin. J Control Release 2008;1431:198-204.
30. Sleeman MA, Watson JD, Murison JG. Neonatal murine epidermal cells express a functional multidrug-resistant pump. J Invest Dermatol 2000;115:19-23.
31. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981;41:1967-72.
32. Fox E, Bates SE. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev Anticancer Ther 2007;7:447-59.
33. Grothey A, Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 2009;9:507-18.
34. Cataisson C, Pearson AJ, Tsien MZ, et al. CXCR2 ligands and G-CSF mediate PKCα-induced intraepidermal inflammation. J Clin Invest 2006;116:2757-66.
35. Wheeler DL, Ness KJ, Oberley TD, Verma AK. Protein kinase Cε is linked to 12-O-tetradecanoylphorbol-13-acetate-induced tumor necrosis factor-α ectodomain shedding and the development of metastatic squamous cell carcinoma in protein kinase Cε transgenic mice. Cancer Res 2003;63:6547-55.
36. Scribner JD, Slaga TJ. Multiple effects of dexamethasone on protein synthesis and hyperplasia caused by a tumor promoter. Cancer Res 1973;33:542-6.
37. Gordon JS, Wolanin PM, Gonzalez AV, et al. Topical N-acetyl-S-farnesyl-L- cysteine inhibits mouse skin inflammation, and unlike dexamethasone, its effects are restricted to the application site. J Invest Dermatol 2008;128:643-54.
38. Hampson P, Kavanagh D, Smith E, Wang K, Lord JM, Ed RG. The anti-tumor agent, ingenol-3-angelate (PEP005), promotes the recruitment of cytotoxic neutrophils by activation of vascular endothelial cells in a PKC-δ dependent manner. Cancer Immunol Immunother 2008;57:1241-51.
39. Gillespie SK, Zhang XD, Hersey P. Ingenol 3-angelate induces dual modes of cell death and differentially regulates tumor necrosis factor-related apoptosis inducing ligand-induced apoptosis in melanoma cells. Mol Cancer Ther 2004;12:1651-58.
40. Elias PM. The skin barrier as an innate immune element. Semin Immunopathol 2007;29:3-14.
41. Hadgraft J, Lane ME. Skin permeation: the years of enlightenment. Int J Pharm 2005;305:2-12.
42. Baron JM, Holler D, Schiffer R, et al. Expression of multiple cytochrome p450 enzymes and multidrug resistance-associated transport proteins in human skin keratinocytes. J Invest Dermatol 2001;116:541-8.
43. Dreuw A, Hermanns HM, Heise R, et al. Interleukin-6-type cytokines upregulate expression of multidrug resistance-associated protein in NHEK and dermal fibroblasts. J Invest Dermatol 2005;124:28-37.
44. Fung KL, Gottesman MM. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta 2009;1794:860-71.
45. Cevc C, Vierl U. Nanotechnology and the transdermal route: a state of the art review and critical appraisal. J Controlled Release 2010;141:277-99.